UPDATE: Goldman Sachs Upgrades Phathom Pharmaceuticals (PHAT) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Stocks face worst month since September, yen swings after BoJ
- Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Oil prices on track to snap two-week losing streak
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Phathom Pharmaceuticals Reports First Quarter 2021 Results and Provides Recent Business Updates
May 11, 2021 8:01 AM EDTPositive Phase 3 trial of vonoprazan in Helicobacter pylori (H. pylori) infection; New Drug Applications (NDAs) targeted for the fourth quarter of 2021U.S. Food and Drug Administration (FDA) grants additional qualified infectious disease product (QIDP) designations to vonoprazan-based regimens with amoxicillin capsules; FDA had previously designated vonoprazan-based regimens with amoxicillin tablets as QIDPInitiated Phase 2 trial evaluating vonoprazan on-demand in non-erosive reflux disease (NERD) disease with large unmet need impacting an estimated more than 40 million people in the U.S.Pivotal Phase 3 PHALCON-EE trial topline results expected in the fourth quarter of 2021... More
Phathom Pharmaceuticals Reports First Quarter 2021 Results and Provides Recent Business Updates
May 11, 2021 8:00 AM EDTPositive Phase 3 trial of vonoprazan in Helicobacter pylori (H. pylori) infection; New Drug Applications (NDAs) targeted for the fourth quarter of 2021U.S. Food and Drug Administration (FDA) grants additional qualified infectious disease product (QIDP) designations to vonoprazan-based regimens with amoxicillin capsules; FDA had previously designated vonoprazan-based regimens with amoxicillin tablets as QIDPInitiated Phase 2 trial evaluating vonoprazan on-demand in non-erosive reflux disease (NERD) disease with large unmet need impacting an estimated more than 40 million people in the U.S.Pivotal Phase 3 PHALCON-EE trial topline results expected in the fourth quarter of 2021... More
